Monday, Feb 28, 1994
South San Francisco, Calif. -- February 28, 1994 --Genentech, Inc. (NYSE: GNE) announced today that it has been issued U.S. patent No. 5,284,763 encompassing all forms of transforming growth factor beta (TGF-ß) made by recombinant technology. The patent covers nucleic acids (DNA and RNA), vectors and host cells used for making recombinant TGF-ß. Genentech is a licensee of a TGF-ß protein patent held by the National Institutes of Health (NIH).
TGF-ß is a tissue growth factor that promotes epidermal and bone growth as well as collagen production, both of which may prove helpful in various wound and bone healing indications. This year, Genentech will begin a Phase I trial with recombinant TGF-ß for the prevention of mucositis, a reaction to cancer chemotherapy that produces acute damage to rapidly proliferating cells lining the mouth and causes ulcers and blistering. TGF-ß may prevent or relieve mucositis by rendering oral tissues less sensitive to the effects of chemotherapy.
Genentech has licensed recombinant TGF-ß to a number of companies including Escalon Ophthalmics, Inc. for ophthalmic indications; Celtrix Pharmaceuticals, Inc. for a variety of indications and DePuy, Inc. for bone repair.
Genentech, Inc. is a pace-setting, international biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. The company has headquarters in South San Francisco, California and is traded on the New York and Pacific Stock exchanges under the symbol GNE.
# # #